Industries > Pharma > Global Hereditary Angioedema Market Forecast 2018-2028

Global Hereditary Angioedema Market Forecast 2018-2028

C1 Esterase Inhibitor, Selective Bradykinin B2 Receptor Antagonist, Kallikrein Inhibitor (Kalbitor), Cinryze, Berinert, Ruconest, Intravenous, Subcutaneous Injection, Oral, Hospital Pharmacies, Retail Pharmacies

PUBLISHED: 23 May 2018
PAGES: 232
PRODUCT CODE: PHA0309
SUBMARKET: Therapeutic Drugs

Clear
WOOCS 2.2.1
SKU: PHA0309 Categories: ,

The global hereditary angioedema market is expected to grow at a CAGR of 8.8% in the first half of the forecast period. In 2017, the C1 Esterase Inhibitor segment held 42% of this market.

How this report will benefit you
Read on to discover how you can exploit the future business opportunities emerging in this sector.

In this brand new 232-page report you will receive 82 tables and 130 figures– all unavailable elsewhere.

The 232-page report provides clear detailed insight into the global hereditary angioedema market. Discover the key drivers and challenges affecting the market.

By ordering and reading our brand-new report today you stay better informed and ready to act.

Report Scope

• Global Hereditary Angioedema Market Forecast from 2018-2028

This report also breaks down the revenue forecast for the global hereditary angioedema market by drug class:
• C1 Esterase Inhibitor: Cinryze, Berinert, Ruconest
• Selective Bradykinin B2 Receptor Antagonist
• Kallikrein Inhibitor (Kalbitor)

This report also provides a market attractiveness index by drug class.

This report also breaks down the revenue forecast for the global hereditary angioedema market by route of administration:
• Intravenous
• Subcutaneous Injection
• Oral

This report also provides a market attractiveness index by route of administration.

This report also breaks down the revenue forecast for the global hereditary angioedema market by distribution channel:
• Hospital Pharmacies
• Retail Pharmacies

This report also provides a market attractiveness index by distribution channel

This report provides individual revenue forecasts to 2028 for these regional and national markets:
• North America: The U.S., Canada
• Latin America: Brazil, Mexico, Rest of Latin America
• Europe: U.K., Germany, Spain, France, Italy, Russia, Rest of Europe
• Asia-Pacific: China, India, Japan, Australia and New Zealand, South Korea, ASEAN, Rest of Asia-Pacific
• Middle East: GCC Countries, Israel, Rest of Middle East
• Africa: South Africa, Central Africa, North Africa

Global Hereditary Angioedema Market Forecast 2018-2028

This report also provides a market attractiveness index by region

The forecast for each regional market is further broken down by drug class, product, route of administration and distribution channel

This report provides a market attractiveness index by drug class, product, route of administration and distribution channel for each regional market

• Our study discusses the selected leading companies that are the major players in the global hereditary angioedema industry:
• BioCryst Pharmaceuticals, Inc.
• CSL Limited
• iBio, Inc.
• Ionis Pharmaceuticals, Inc.
• Pharming Group NV
• Santarus, Inc.
• Shire PLC

• This report discusses factors that drive and restrain the market, as well as trends and opportunities.

Visiongain’s study is intended for anyone requiring commercial analyses for the global hereditary angioedema market. You find data, trends and predictions.

Buy our report today Global Hereditary Angioedema Market Forecast 2018-2028: C1 Esterase Inhibitor, Selective Bradykinin B2 Receptor Antagonist, Kallikrein Inhibitor (Kalbitor), Cinryze. Berinert, Ruconest, Intravenous, Subcutaneous Injection, Oral, Hospital Pharmacies, Retail Pharmacies.

Visiongain is a trading partner with the US Federal Government
CCR Ref number: KD4R6

Download sample pages

Complete the form below to download your free sample pages for Global Hereditary Angioedema Market Forecast 2018-2028


Download sample pages

Complete the form below to download your free sample pages for Global Hereditary Angioedema Market Forecast 2018-2028


Latest Pharma news

Visiongain Publishes Cell-Based Assays Market Report to 2030

Growing incidence of chronic diseases; increasing R&D investment for drug discovery research and Growing Adoption of High-Throughput Screening Methodologies are some of the major factors that propel the market growth.

09 April 2021

READ

Visiongain Publishes Cancer Biologics Therapies Market Report 2021-2031

The main drivers for the growth include technological advancements in the development of novel biomarkers, rising preference for minimally or less invasive surgeries, increasing cancer awareness leading to growth in cancer cases, and growing disposable income in emerging economies.

06 April 2021

READ

Visiongain Publishes Artificial Intelligence (AI) in Drug Discovery Market Report 2021-2031

Factors such as increasing data volumes for analysis, quick turnaround time for the discovery and development new drug, computing power, AI also helps in targeted manufacturing and others drive the market growth.

01 April 2021

READ

Visiongain Publishes Inhalation & Nasal Spray Generic Drugs Market Report 2021-2031

Rising prevalence of chronic respiratory diseases including asthma, COPD, and allergic rhinitis; rising geriatric population, escalating investment in drug R&D by biopharmaceutical & pharmaceutical companies; growing respiratory health care awareness; and new product launches worldwide are some of the major factors that boosting the growth of global inhalation & nasal spray generic drugs market.

31 March 2021

READ

Categories